- Global Pharma News & Resources

Nasal Polyps Treatment Market Trends 2020: Comprehensive Insights on Top Key Players, Technological Scope, Revenue Status, Current Trends and Future Investments by 2027

Global Nasal Polyps Treatment Market

Nasal polyps are benign growths occurring inside the paranasal sinuses, lining nasal passages. The size of the polyps may vary and can either grow individually or be found in clusters. These polyps can cause severe infections and breathing difficulties, and could even lead to sleep apnea in certain cases. Nasal polyps can be caused due to asthma, allergic infections, sinus infections, cystic fibrosis, etc.

Request to view Sample Report:

Global Nasal Polyps Treatment Market Drivers

The key players in the global nasal polyps treatment market have constantly been focusing on the development of novel approaches for the treatment of this condition, which is expected to impel the global market growth. For instance, in April 2018, Intersect ENT Inc. launched a product, SINUVA. It is a sinus implant and used for treating nasal polyps. It is a new way of treatment in patients with the past sinus surgeries. This implant contains 1.35 mg mometasone furoate which is delivered, directly to the polyps. It is implanted for a definite period of time (90 days).

Furthermore, in June 2019, Novartis AG revealed the phase III clinical trial study of Xolair, Omalizumab. It is a monoclonal antibody used for treating nasal polyps. It tends to target and block the immunoglobulin E. It was observed that the medication was generally well-tolerated in patients. Hence, such developments of treatment for nasal polyps are expected to fuel the global nasal polyps treatment market development.

To understand Research Methodology, please click

Moreoevr, increasing approvals from regulatory bodies for nasal polyps treatment is expected to drive the global nasal polyps treatment market growth in the coming years. For instance, in June 2019, Dupixent received an approval from the U.S. Food & Drug Administration (FDA) for treating nasal polyps. It was manufactured by Sanofi in partnership with Regeneron Pharmaceuticals Inc. It is the first treatment that got approved for chronic rhinosinusitis with nasal polyps. It is used when the oral steroids are unable to control the inflammation and to avoid the surgical method. Hence, such approvals are expected to impact positively on the global nasal polyps treatment market growth.

Global Nasal Polyps Treatment Market – Regional Overview

North America is expected to hold a dominant position in the global nasal polyps treatment market. Factors such as high prevalence of asthma contribute majorly to the regional market growth. Nasal polyps are triggered due to asthma and also at the same time nasal polyps can cause asthma. For instance, according to American Academy of Allergy, Asthma & Immunology 2017, published data, around 28% to 40% patients with nasal polyps are diagnosed with asthma. According to the same source, around 19% to 39% patients get nasal polyps who are already suffering from asthma. Such increasing prevalence may increase the demand for treatment of nasal polyps thereby expected to propel the global nasal polyps treatment market growth.

Global Nasal Polyps Treatment Market Restraints

Numerous side effects associated with the medication used for the treatment of nasal polyps may restrain the global nasal polyps treatment market growth in the foreseeable future. The mometasone furoate monohydrate can result in common side effects, such as headache, sore throat, muscle and joint pain, nausea, and in some cases, bleeding of the nose.

Global Nasal Polyps Treatment Market – Leading Players

Some of the major players operating in the global nasal polyps treatment market include Intersect ENT Inc., GlaxoSmithKline Plc, Merck Sharp and Dohme Corp, Teva Branded Pharmaceutical Products R and D Inc., Norton Waterford Ltd, Sanofi, Regeneron Pharmaceuticals Inc., Fougera Pharmaceuticals Inc., Glenmark, and Taro Pharmaceuticals Industries Ltd.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Market Taxonomy

By Drug Type,

  • Fluticasone
  • Mometasone
  • Fluticasone
  • Beclomethasone
  • Prednisone
  • Others

By Route of Administration,

  • Oral
  • Nasal
  • Injectable

By Distribution Channel,

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region,

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 13-Jan-2021